作者
Zev A. Wainberg,Yoon‐Koo Kang,Keun‐Wook Lee,Seung Tae Kim,Joseph Chao,Daniel V.T. Catenacci,Sung Yong Oh,Heloisa Prado Soares,Jennifer Eva Selfridge,Yongjun Cha,Roland T. Skeel,Hyung‐Don Kim,Anh Tuan Tran,Achim K. Moesta,Tracy dela Cruz,Anil K. Singhal,Thomas Michael Jahn,Farshid Dayyani
摘要
Abstract Background: The ecto-ATPase CD39 is the rate-limiting enzyme in the adenosine pathway that plays an important immune regulatory role. Preclinically, inhibition of CD39 by TTX-030, a first-in-class fully human anti-CD39 antibody, reversed immunosuppression by maintaining high levels of immune-stimulatory extracellular ATP while reducing suppressive adenosine. The addition of nivolumab to chemotherapy has recently become the standard of care of 1st-line (1L) treatment of locally advanced or metastatic (LA/M) gastric cancer but further improvements are needed. Methods: An expansion cohort of Study TTX-030-002 (ongoing, US and South Korea) is evaluating the safety and efficacy of the combination of TTX-030, budigalimab (anti-PD-1) and FOLFOX for the 1L treatment of patients (pts) with LA/M HER2− gastric/GEJ adenocarcinoma. The primary objective was to assess safety and tolerability. Secondary endpoints included ORR by RECIST/iRECIST, and PFS. Correlative studies included the analysis of intratumoral expression of CD39 and PD-L1. Results: Forty-four pts were enrolled with the median age [range] of 61 [30−81] years, 41% were female, and 57% were Asian. Pts had an ECOG of 0 (39%) or 1 (61%), 70% had gastric adenocarcinoma, 30% had GEJ adenocarcinoma. As of the safety data cutoff (Nov 19, 2021), 39 pts (89%) experienced at least 1 treatment-emergent AE (any Grade, regardless of relatedness). Twenty-one pts (48%) experienced at least 1 AE considered related to TTX-030 (any Grade); five (11%) experienced a Grade 3/4 AE considered related to TTX-030. There were no Grade 5 TEAEs. Eleven pts (25%) had experienced SAEs; none were considered related to TTX-030. The most common AEs by preferred term (any Grade, regardless of relatedness) in ≥10 pts were nausea (52%), neutrophil count decreased (39%), decreased appetite (30%), diarrhea (25%), and fatigue (23%). The most common Grade ≥3 AEs (regardless of relatedness) in ≥2 pts were neutrophil count decreased (27%), febrile neutropenia (5%), hypokalemia (5%). As of the efficacy data cutoff (Dec 2, 2021), the median time [range] on study was 139 [8−375] days. Among 38 efficacy evaluable pts, 23 pts experienced PR or better as best response (PR: n=21; CR: n=2; ORR=61%), 12 experienced SD, and 3 had PD. Thirty-six of the 38 efficacy-evaluable patients had known PD-L1 Combined Positive Score (CPS); response rates were 4/10 (CPS <1), 8/10 (CPS ≥1 and <5), and 11/16 (CPS ≥ 5). Conclusions: Preliminary results indicate that the combination of TTX-030, budigalimab and FOLFOX exhibited promising efficacy as 1L treatment of LA/M gastric/GEJ cancer regardless of CPS status and has a manageable safety profile without evidence of excessive toxicities. To our knowledge, this represents the first report of an anti-CD39 antibody in combination with chemo-immunotherapy in gastric cancer. Updated clinical and biomarker data will be included in the final presentation. Citation Format: Zev Wainberg, Yoon-Koo Kang, Keun-Wook Lee, Seung Tae Kim, Joseph Chao, Daniel Catenacci, Sung Yong Oh, Heloisa P. Soares, J. Eva Selfridge, Yongjun Cha, Roland T. Skeel, Hyung-Don Kim, Anh Tran, Achim Moesta, Tracy Dela Cruz, Anil Singhal, Thomas M. Jahn, Farshid Dayyani. Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the first line treatment of locally advanced or metastatic gastric/GEJ cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT015.